Avadel Pharmaceuticals
16640 Chesterfield Grove Road, Suite 200
Chesterfield
MO
63005
United States
Website: https://www.avadel.com/
304 articles about Avadel Pharmaceuticals
-
Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
5/18/2022
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25 at 8:30 a.m. E.T.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2022 Financial Results on May 9
5/2/2022
Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 9, 2022, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2022.
-
Clinical Catch-Up: COVID-19, AAN, ACC
4/11/2022
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look. -
Avadel Pharmaceuticals Announces Publication of Positive Secondary Endpoint Data from Pivotal Phase 3 REST-ON Trial
4/6/2022
Avadel Pharmaceuticals plc announced today the publication of positive secondary endpoint data from its pivotal Phase 3 REST-ON trial of FT218 in CNS Drugs, a peer-reviewed medical journal focused on the treatment of psychiatric and neurological disorders.
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - Mar 22, 2022
3/22/2022
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 17th
3/14/2022
Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 17, 2022, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2021.
-
Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022
3/11/2022
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presented in eight posters at the World Sleep 2022 congress in Rome.
-
Avadel to Present New Clinical Data at World Sleep 2022
3/1/2022
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced it will present eight posters at World Sleep 2022, taking place March 11-16 in Rome, Italy.
-
Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer
2/14/2022
Avadel Pharmaceuticals plc today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer.
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
11/22/2021
Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference: Participation starting on Monday, November 29.
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in November
11/9/2021
Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences in November: Stifel’s 2021 Virtual Healthcare Conference: Fireside chat on Tuesday, November 16 at 8:00 a.m. E.T.
-
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2021 Financial Results on November 8th
11/1/2021
Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.
-
Avadel Presents New Data Supporting Clinical Benefit with Once-at-Bedtime FT218 and Preference for Once-Nightly Dosing in Patients with Narcolepsy at CHEST 2021
10/19/2021
Avadel Pharmaceuticals plc today announced new data from the completed pivotal Phase 3 REST-ON clinical trial of FT218, also known as ON-SXB.
-
Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for FT218 for Patients with Narcolepsy
10/15/2021
Avadel Pharmaceuticals plc, a company focused on transforming medicines to transform lives, announced that the U.S. Food and Drug Administration notified the company that the review of the New Drug Application for FT218 is still ongoing, and action will likely not be taken in October.
-
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021
9/2/2021
Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:
-
Avadel Pharmaceuticals to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021
7/7/2021
Avadel Pharmaceuticals plc announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Wednesday, July 14 at 11:00 a.m. ET.
-
Avadel Pharmaceuticals Expands Leadership Team with Three Strategic Hires
6/2/2021
Bolsters team with addition of established biopharma industry leaders in advance of anticipated regulatory approval and commercialization of once-nightly FT218 for narcolepsy
-
Avadel Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference - May 25, 2021
5/25/2021
Avadel Pharmaceuticals plc, a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Tuesday, June 1 at 9:00 a.m. ET.
-
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
5/10/2021
Announced FDA acceptance of NDA for once-nightly FT218 and an October 15, 2021 target action PDUFA date Presented positive secondary endpoint data at the AAN 2021 Annual Meeting, which further highlights the overall clinical value proposition of FT218 FT218 launch preparation progressing Management to host a conference call today at 8:30 a.m. ET
-
Avadel Presents New Data from its Pivotal REST-ON Phase 3 Trial of FT218, once-nightly sodium oxybate, at the 2021 American Academy of Neurology Annual Meeting
4/17/2021
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses